Hepion Pharmaceuticals Inc
said on Monday its treatment met the main goal of improving
liver function in patients with a type of fatty liver disease in
a mid-stage study trial, sending its shares 45%. | May 22, 2023
Hepion Pharmaceuticals Inc
said on Monday its treatment met the main goal of improving
liver function in patients with a type of fatty liver disease in
a mid-stage study trial. . | May 22, 2023
EDISON, N.J., May 10, 2023 Hepion Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company focused on Artificial Intelligence -driven therapeutic drug development for the treatment of. | May 10, 2023